Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
| Image |  |
|---|---|
| Description | scientific article published on 11 May 2017 |
| Author/s |
author: Tomasz M Beer Susan Halabi |
| Publication date | May 11, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |